BRPI0415620A - uso de cátions metálicos para melhorar a atividade funcional de anticorpos - Google Patents

uso de cátions metálicos para melhorar a atividade funcional de anticorpos

Info

Publication number
BRPI0415620A
BRPI0415620A BRPI0415620-0A BRPI0415620A BRPI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A BR PI0415620 A BRPI0415620 A BR PI0415620A
Authority
BR
Brazil
Prior art keywords
metal cations
functional activity
improve antibody
antibody functional
improve
Prior art date
Application number
BRPI0415620-0A
Other languages
English (en)
Inventor
Dominique Bourel
Arnaud Glacet
Sylvie Jorieux
Enrico Stura
Frederic Ducancel
Jean-Luc Teillaud
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0415620A publication Critical patent/BRPI0415620A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

"USO DE CáTIONS METáLICOS PARA MELHORAR A ATIVIDADE FUNCIONAL DE ANTICORPOS". A presente invenção refere-se ao uso de cátions metálicos, em particular zinco, para melhorar a atividade funcional de anticorpos. Mais particularmente, a referida invenção é concernida com composições farmacêuticas, compreendendo anticorpos com cátions metálicos.
BRPI0415620-0A 2003-10-20 2004-10-20 uso de cátions metálicos para melhorar a atividade funcional de anticorpos BRPI0415620A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312228A FR2861079B1 (fr) 2003-10-20 2003-10-20 Utilisation de cations metalliques divalents pour l'amelioration de l'activite fonctionnelle des anticorps.
PCT/FR2004/002687 WO2005040216A2 (fr) 2003-10-20 2004-10-20 Utilisation de cations metalliques pour cristalliser le fragment fc d’un anticorps rhesus d

Publications (1)

Publication Number Publication Date
BRPI0415620A true BRPI0415620A (pt) 2006-12-12

Family

ID=34385293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415620-0A BRPI0415620A (pt) 2003-10-20 2004-10-20 uso de cátions metálicos para melhorar a atividade funcional de anticorpos

Country Status (8)

Country Link
EP (1) EP1689785A2 (pt)
JP (1) JP2007537990A (pt)
AU (1) AU2004283925A1 (pt)
BR (1) BRPI0415620A (pt)
CA (1) CA2542928A1 (pt)
FR (1) FR2861079B1 (pt)
IL (1) IL175026A0 (pt)
WO (1) WO2005040216A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
FR2942799B1 (fr) 2009-03-06 2011-02-25 Lfb Biotechnologies Anticorps monoclonal anti-rhesus d
EP2787006B1 (en) * 2013-04-02 2018-02-28 Miltenyi Biotec GmbH Anti-CD8 antibody which binding is Ca2+ dependent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2081213A1 (en) * 1990-05-08 1991-11-09 Richard A. Lerner Metal binding proteins
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
FR2894982A1 (fr) * 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs

Also Published As

Publication number Publication date
IL175026A0 (en) 2006-08-20
JP2007537990A (ja) 2007-12-27
CA2542928A1 (fr) 2005-05-06
WO2005040216A2 (fr) 2005-05-06
FR2861079B1 (fr) 2007-09-28
EP1689785A2 (fr) 2006-08-16
FR2861079A1 (fr) 2005-04-22
AU2004283925A1 (en) 2005-05-06
WO2005040216A3 (fr) 2005-10-20

Similar Documents

Publication Publication Date Title
AR050254A1 (es) Intermediarios y procesos para preparar dichos intermediarios utiles en la fabricacion de pirrolotriazinas
BRPI0513738A (pt) sensor transdutor acústico eletromagnético flexìvel
BR0211039A (pt) Composição condicionadora para os cabelos e uso de uma composição condicionadora para os mesmos
EP1938155A4 (en) BUSINESS PROCESS EXECUTE ENGINE
BR0314814A (pt) Variantes otimizadas de fc e métodos para sua geração
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
HN2002000319A (es) Benzamida, heteroarilamida y amidas inversas
ECSP067110A (es) Derivados de 2-carbamida-4-feniltiazol, su preparación y su aplicación en terapéutica
AR047551A1 (es) Compuestos activos antritranspirantes de aluminio/ zirconio / glicina, estabilizados con betaina
BRPI0508732A (pt) composição de um produto de beleza para limpeza
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
FR2831433B1 (fr) Composition topique solide
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
EP1704853A3 (en) Water-in-silicone emulsion compositions
BRPI0607349A2 (pt) combinação de xolair com agente imunossupressor
WO2007014137A3 (en) 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents
BR0300119A (pt) Composição aquosa, e, estrutura compósita
TW200724159A (en) Stable emulsion composition
BRPI0415620A (pt) uso de cátions metálicos para melhorar a atividade funcional de anticorpos
DE59914210D1 (de) Kosmetische oder medizinische zubereitung für die topische anwendung
DE60323138D1 (de) Kombinationsarzneimittel aus r,r-formoterol und ciclesonide
AR063597A1 (es) Nueva sal
GT200500250A (es) Hexadecasacaridos biotinilados, su preparacion y su utilizacion
BRPI0406466A (pt) Composição oral e uso de perlita
WO2004075028A3 (en) Systems and methods for variable rebate and incentive programs

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LFB BIOTECHNOLOGIES (FR)

Free format text: TRANSFERIDO DE: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.